GOIZ ZAINDU study: a FINGER-like multidomain lifestyle intervention feasibility randomized trial to prevent dementia in Southern Europe.
Cognitive impairment
Dementia prevention
Lifestyle
Multidomain intervention
Randomized trial
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
27 Feb 2024
27 Feb 2024
Historique:
received:
11
09
2023
accepted:
16
01
2024
medline:
28
2
2024
pubmed:
28
2
2024
entrez:
27
2
2024
Statut:
epublish
Résumé
GOIZ ZAINDU ("caring early" in Basque) is a pilot study to adapt the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) methodology to the Basque population and evaluate the feasibility and adherence to a FINGER-like multidomain intervention program. Additional aims included the assessment of efficacy on cognition and data collection to design a large efficacy trial. GOIZ ZAINDU is a 1-year, randomized, controlled trial of a multidomain intervention in persons aged 60+ years, with Cardiovascular Risk Factors, Aging and Dementia (CAIDE) risk score ≥ 6, no diagnosis of dementia, and below-than-expected performance in at least one of three cognitive screening tests. Randomization to a multidomain intervention (MD-Int) or regular health advice (RHA) was stratified by sex, age (>/≤ 75), and cognitive status (mild cognitive impairment (MCI)/normal cognition). MD-Int included cardiovascular risk factor control, nutritional counseling, physical activity, and cognitive training. The primary outcomes were retention rate and adherence to the intervention program. Exploratory cognitive outcomes included changes in the Neuropsychological Test Battery z-scores. Analyses were performed according to the intention to treat. One hundred twenty-five participants were recruited (mean age: 75.64 (± 6.46); 58% women). The MD-Int (n = 61) and RHA (n = 64) groups were balanced in terms of their demographics and cognition. Fifty-two (85%) participants from the RHA group and 56 (88%) from the MD-Int group completed the study. More than 70% of the participants had high overall adherence to the intervention activities. The risk of cognitive decline was higher in the RHA group than in the MD-Int group in terms of executive function (p =.019) and processing speed scores (p =.026). The GOIZ-ZAINDU study proved that the FINGER methodology is adaptable and feasible in a different socio-cultural environment. The exploratory efficacy results showed a lower risk of decline in executive function and processing speed in the intervention group. These results support the design of a large-scale efficacy trial. GOIZ ZAINDU feasibility trial was approved and registered by the Euskadi Drug Research Ethics Committee (ID: PI2017134) on 23 January 2018. Retrospectively registered in ClinicalTrials.gov (NCT06163716) on 8 December 2023.
Sections du résumé
BACKGROUND
BACKGROUND
GOIZ ZAINDU ("caring early" in Basque) is a pilot study to adapt the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) methodology to the Basque population and evaluate the feasibility and adherence to a FINGER-like multidomain intervention program. Additional aims included the assessment of efficacy on cognition and data collection to design a large efficacy trial.
METHOD
METHODS
GOIZ ZAINDU is a 1-year, randomized, controlled trial of a multidomain intervention in persons aged 60+ years, with Cardiovascular Risk Factors, Aging and Dementia (CAIDE) risk score ≥ 6, no diagnosis of dementia, and below-than-expected performance in at least one of three cognitive screening tests. Randomization to a multidomain intervention (MD-Int) or regular health advice (RHA) was stratified by sex, age (>/≤ 75), and cognitive status (mild cognitive impairment (MCI)/normal cognition). MD-Int included cardiovascular risk factor control, nutritional counseling, physical activity, and cognitive training. The primary outcomes were retention rate and adherence to the intervention program. Exploratory cognitive outcomes included changes in the Neuropsychological Test Battery z-scores. Analyses were performed according to the intention to treat.
RESULTS
RESULTS
One hundred twenty-five participants were recruited (mean age: 75.64 (± 6.46); 58% women). The MD-Int (n = 61) and RHA (n = 64) groups were balanced in terms of their demographics and cognition. Fifty-two (85%) participants from the RHA group and 56 (88%) from the MD-Int group completed the study. More than 70% of the participants had high overall adherence to the intervention activities. The risk of cognitive decline was higher in the RHA group than in the MD-Int group in terms of executive function (p =.019) and processing speed scores (p =.026).
CONCLUSIONS
CONCLUSIONS
The GOIZ-ZAINDU study proved that the FINGER methodology is adaptable and feasible in a different socio-cultural environment. The exploratory efficacy results showed a lower risk of decline in executive function and processing speed in the intervention group. These results support the design of a large-scale efficacy trial.
TRIAL REGISTRATION
BACKGROUND
GOIZ ZAINDU feasibility trial was approved and registered by the Euskadi Drug Research Ethics Committee (ID: PI2017134) on 23 January 2018. Retrospectively registered in ClinicalTrials.gov (NCT06163716) on 8 December 2023.
Identifiants
pubmed: 38413990
doi: 10.1186/s13195-024-01393-z
pii: 10.1186/s13195-024-01393-z
doi:
Banques de données
ClinicalTrials.gov
['NCT06163716']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
44Investigateurs
I Aquizu
(I)
M A Arrondo
(MA)
E Baztarrika
(E)
L Etxeberria
(L)
E García-Arrea
(E)
M García-Domínguez
(M)
E Imaz
(E)
M Iparragirre
(M)
M Iridoy
(M)
A Larrea
(A)
M D López
(MD)
F Martin
(F)
A Olaskoaga
(A)
P Pacheco
(P)
A M Pérez-Rodiguez
(AM)
Y Porres
(Y)
M Ruibal
(M)
B San Juan
(B)
M J Tilves
(MJ)
E Zapirain
(E)
Informations de copyright
© 2024. The Author(s).
Références
Collaborators G 2016 D, Nichols E, Szoeke CEI, Vollset SE, Abbasi N, Abd-Allah F, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88–106.
doi: 10.1016/S1474-4422(18)30403-4
Soto-Gordoa M, Arrospide A, Moreno-Izco F, Martínez-Lage P, Castilla I, Mar J. Projecting burden of dementia in Spain, 2010–2050: Impact of Modifying Risk factors. J Alzheimer’s Dis. 2015;48:721–30.
doi: 10.3233/JAD-150233
Lisko I, Kulmala J, Annetorp M, Ngandu T, Mangialasche F, Kivipelto M. How can dementia and disability be prevented in older adults: where are we today and where are we going? J Intern Med. 2021;289(6):807-30.
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413–46.
doi: 10.1016/S0140-6736(20)30367-6
pubmed: 32738937
pmcid: 7392084
Solomon A, Kivipelto M, Soininen H. Prevention of Alzheimer’s disease: moving backward through the lifespan. J Alzheimer’s Dis. 2013;33(Suppl 1):S465-9.
Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–94.
doi: 10.1016/S1474-4422(14)70136-X
pubmed: 25030513
Wu Y-T, Beiser AS, Breteler MMB, Fratiglioni L, Helmer C, Hendrie HC, et al. The changing prevalence and incidence of dementia over time — current evidence. Nat Rev Neurol. 2017;13:327–39.
doi: 10.1038/nrneurol.2017.63
pubmed: 28497805
Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med. 2013;369:2275–7.
doi: 10.1056/NEJMp1311405
pubmed: 24283198
pmcid: 4130738
Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5:735–41.
doi: 10.1016/S1474-4422(06)70537-3
pubmed: 16914401
Ecay-Torres M, Estanga A, Tainta M, Izagirre A, Garcia-Sebastian M, Villanua J, et al. Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults. Neurology. 2018;91:e217-26.
doi: 10.1212/WNL.0000000000005824
pubmed: 29898969
O’Brien JT, Firbank MJ, Ritchie K, Wells K, Williams GB, Ritchie CW, et al. Association between midlife dementia risk factors and longitudinal brain atrophy: the PREVENT-Dementia study. J Neurol Neurosurg Psychiatry. 2019;91:158-61.
Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255–63.
doi: 10.1016/S0140-6736(15)60461-5
pubmed: 25771249
van Charante EP, Richard E, Eurelings LS, van Dalen J-W, Ligthart SA, van Bussel EF, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. Lancet. 2016;388:797–805.
doi: 10.1016/S0140-6736(16)30950-3
Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16:377–89.
doi: 10.1016/S1474-4422(17)30040-6
pubmed: 28359749
Delrieu J, Payoux P, Carrié I, Cantet C, Weiner M, Vellas B, et al. Multidomain intervention and/or omega-3 in nondemented elderly subjects according to amyloid status. Alzheimer’s Dement. 2019;15:1392–401.
doi: 10.1016/j.jalz.2019.07.008
Kivipelto M, Mangialasche F, Snyder HM, Allegri R, Andrieu S, Arai H, et al. World-Wide FINGERS Network: a global approach to risk reduction and prevention of dementia. Alzheimer’s Dement J Alzheimer’s Assoc. 2020;16:1078–94.
doi: 10.1002/alz.12123
Chew KA, Xu X, Siongco P, Villaraza S, Phua AKS, Wong ZX, et al. SINgapore GERiatric intervention study to reduce physical frailty and cognitive decline (SINGER)–pilot: a feasibility study. Alzheimer’s Dement Transl Res Clin Interven. 2021;7:e12141.
doi: 10.1002/trc2.12141
Olazarán J, Hoyos-Alonso MC, del Ser T, Barral GA, Conde-Sala JL, Bermejo-Pareja F, et al. Aplicación práctica de los test cognitivos breves. Neurología. 2016;31:183–94.
doi: 10.1016/j.nrl.2015.07.009
pubmed: 26383062
Rami L, Molinuevo J, Sanchez-Valle R, Bosch B, Villar A. Screening for amnestic mild cognitive impairment and early Alzheimer’s disease with M@T (Memory Alteration Test) in the primary care population. Int J Geriatr Psychiatry. 2007;22:294–304.
doi: 10.1002/gps.1672
pubmed: 16998781
Carnero-Pardo C, Espejo-Martinez B, Lopez-Alcalde S, Espinosa-Garcia M, Saez-Zea C, Vilchez-Carrillo R, et al. Effectiveness and costs of phototest in dementia and cognitive impairment screening. BMC Neurol. 2011;11:92.
doi: 10.1186/1471-2377-11-92
pubmed: 21801419
pmcid: 3160880
Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65:559–64.
doi: 10.1212/01.wnl.0000172958.95282.2a
pubmed: 16116116
Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152:726.
doi: 10.7326/0003-4819-152-11-201006010-00232
pubmed: 20335313
Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.
doi: 10.1136/bmj.i5239
pubmed: 27777223
pmcid: 5076380
Petersen R. Mild cognitive impairment as a diagnostic entity. J Int Med. 2004;256:183–94.
doi: 10.1111/j.1365-2796.2004.01388.x
Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. New Engl J Med. 2018;378:e34.
doi: 10.1056/NEJMoa1800389
pubmed: 29897866
van de Rest O, Berendsen AA, Haveman-Nies A, de Groot LC. Dietary patterns, cognitive decline, and dementia: a systematic review. Adv Nutr. 2015;6:154–68.
doi: 10.3945/an.114.007617
pubmed: 25770254
pmcid: 4352174
Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, Ruiz-Gutiérrez V, Covas MI, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med. 2006;145:1.
doi: 10.7326/0003-4819-145-1-200607040-00004
pubmed: 16818923
Kivipelto M, Solomon A, Ahtiluoto S, Ngandu T, Lehtisalo J, Antikainen R, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimer’s Dement. 2013;9:657–65.
doi: 10.1016/j.jalz.2012.09.012
Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol-chicago. 2007;64:1323–9.
doi: 10.1001/archneur.64.9.1323
pubmed: 17846273
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
doi: 10.1016/0022-3956(75)90026-6
pubmed: 1202204
Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthrit Care Res. 2011;63:S467-72.
doi: 10.1002/acr.20561
Agarwala P, Salzman SH. Six-minute walk test clinical role, technique, coding, and reimbursement. Chest. 2020;157:603–11.
doi: 10.1016/j.chest.2019.10.014
pubmed: 31689414
Fernández-Ballesteros R, Zamarrón MD, Rudinger G, Schroots JJF, Hekkinnen E, Drusini A, et al. Assessing competence: the European Survey on Aging Protocol (ESAP). Gerontology. 2004;50:330–47.
doi: 10.1159/000079132
pubmed: 15331863
Strandberg TE, Levälahti E, Ngandu T, Solomon A, Kivipelto M, Group F, et al. Health-related quality of life in a multidomain intervention trial to prevent cognitive decline (FINGER). Eur Geriatr Med. 2017;8:164–7.
doi: 10.1016/j.eurger.2016.12.005
Xu X, Chew KA, Wong ZX, Phua AKS, Chong EJY, Teo CKL, et al. The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER): study design and protocol. J Prev Alzheimer’s Dis. 2022;9:40–8.
Coley N, Ngandu T, Lehtisalo J, Soininen H, Vellas B, Richard E, et al. Adherence to multidomain interventions for dementia prevention: data from the FINGER and MAPT trials. Alzheimer’s Dement. 2019;5:729-41.
Ngandu T, Lehtisalo J, Korkki S, Solomon A, Coley N, Antikainen R, et al. The effect of adherence on cognition in a multidomain lifestyle intervention (FINGER). Alzheimer’s Dement. 2021;18:1325-34.
Belleville S, Cloutier S, Mellah S, Willis S, Vellas B, Andrieu S, et al. Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia. Alzheimer’s Dement. 2022;18:2140–50.
doi: 10.1002/alz.12544
Fratiglioni L, Marseglia A, Dekhtyar S. Ageing without dementia: can stimulating psychosocial and lifestyle experiences make a difference? Lancet Neurol. 2020;19:533–43.
doi: 10.1016/S1474-4422(20)30039-9
pubmed: 32470425
Ngandu T, Lehtisalo J, Levälahti E, Laatikainen T, Lindström J, Peltonen M, et al. Recruitment and baseline characteristics of participants in the Finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER)—a randomized controlled lifestyle trial †. Int J Environ Res Pu. 2014;11:9345–60.
doi: 10.3390/ijerph110909345
Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat Rev Neurol. 2018;14:1.
doi: 10.1038/s41582-018-0070-3
Kulmala J, Ngandu T, Havulinna S, Levälahti E, Lehtisalo J, Solomon A, et al. The effect of multidomain lifestyle intervention on daily functioning in older people. J Am Geriatr Soc. 2019;67:1138–44.
doi: 10.1111/jgs.15837
pubmed: 30809801
Kulmala J, Ngandu T, Kivipelto M. Prevention matters: time for global action and effective implementation. J Alzheimer’s Dis. 2018;Preprint:S191–8.
Ngandu T, Kulmala J, Antikainen R, Laatikainen T, Soininen H, Strandberg T, et al. Use of health care services among older adults participating in a multidomain lifestyle intervention to prevent cognitive impairment (FINGER). Alzheimer’s Dement. 2018;14:P1363.
Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.
doi: 10.1136/bmj.38875.675486.55
pubmed: 16790458
pmcid: 1488752
Rosenberg A, Mangialasche F, Ngandu T, Solomon A, Kivipelto M. Multidomain interventions to prevent cognitive impairment, Alzheimer’s disease, and dementia: from FINGER to World-Wide FINGERS. J Prev Alzheimer’s Dis. 2019;7:29-36.
Kivipelto M, Mangialasche F, Ngandu T, Network W, Martín E, Kivipelto M, et al. World Wide Fingers will advance dementia prevention. Lancet Neurol. 2018;17:27.
doi: 10.1016/S1474-4422(17)30431-3
pubmed: 29263003